Kymera Therapeutics (KYMR) Corporate presentation summary

Decade of innovation and strategic focus

• Established targeted protein degradation (TPD) as a reproducible innovation engine, advancing six first-in-class molecules into the clinic since 2016.

• Focused on historically undrugged, genetically validated targets in immunology, aiming to commercialize oral medicines with biologics-like activity.

• Pipeline includes wholly-owned and partnered oral degraders for STAT6, IRF5, IRAK4, and CDK2, targeting large, underserved patient populations.

Market opportunity and unmet need

• Over 160 million patients diagnosed with immunological diseases in major markets, but only 3% receive advanced therapies, mostly injectables.

• Advanced systemic therapies generate over $100B in annual sales, yet most patients remain untreated or on non-advanced therapies.

• Oral therapies are highly preferred by patients, with >90% indicating willingness to switch from injectables if efficacy and safety are comparable.

KT-621: First-in-class oral STAT6 degrader

• KT-621 demonstrated deep STAT6 degradation in blood and skin, robust biomarker reductions, and meaningful clinical improvements in atopic dermatitis (AD), asthma, and allergic rhinitis.

• Phase 1b AD data showed efficacy and safety comparable or superior to dupilumab, with rapid, robust improvements in EASI, SCORAD, itch, and quality of life measures.

• Enrollment complete in Phase 2b AD trial (BROADEN2), with data expected by year-end 2026; Phase 3 trials planned for mid-2027.